NCT06104839View on ClinicalTrials.gov

Safety and Efficacy of Oral NXC-736 in Adult Participants with Moderate and Severe Alopecia Areata

PHASE2RecruitingINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

June 24, 2025

Study Completion Date

June 30, 2025

Conditions

Alopecia Areata

Interventions

DRUG

NXC736

oral administration

DRUG

Placebo

oral administration

Trial Locations (2)

03080

RECRUITING

Seoul National University Hospital., Seoul

05278

RECRUITING

Kyung Hee University Hospital at Gangdong, Seoul

Sponsors

Lead Sponsor

NEXTGEN Bioscience

All Listed Sponsors

lead

NEXTGEN Bioscience

INDUSTRY